Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma

• Published in: Cancer Immunology, Immunotherapy Vol. 71; no. 9; pp. 2277 - 2286
• Main Authors: Lim, Chwee Ming, Liou, Anthony, Poon, Michelle, Koh, Liang Piu, Tan, Lip Kun, Loh, Kwok Seng, Petersson, Bengt Fredrik, Ting, Eric, Campana, Dario, Goh, Boon Cher, Shimasaki, Noriko
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2022; Springer Nature B.V
• Subjects: Antibodies, Monoclonal, Humanized - pharmacology; Antibody-Dependent Cell Cytotoxicity; Cancer Research; CD16 antigen; Cell culture; Cell Line, Tumor; Cetuximab - pharmacology; Cetuximab - therapeutic use; Chemotherapy; Clinical Trial Report; Cytotoxicity; Epidermal growth factor; Epidermal growth factor receptors; Humans; Immunology; Killer Cells, Natural; Medicine; Medicine & Public Health; Metastases; Metastasis; Monoclonal antibodies; Nasopharyngeal carcinoma; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Neoplasms - drug therapy; Natural killer cells; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - metabolism; Oncology; Patients; Peripheral blood; Safety; Side effects; Targeted cancer therapy; Throat cancer; Tumors; Nasopharyngeal carcinoma; Clinical trial; NK cell therapy; Cetuximab; EGFR

Background Nasopharyngeal carcinoma (NPC) cells express high levels of epidermal growth factor receptor (EGFR). Cetuximab is an anti-EGFR monoclonal antibody that promotes natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) via engagement of CD16. We studied safety and...